MARKET

IMVT

IMVT

Immunovant Inc
NASDAQ
25.75
+0.11
+0.43%
After Hours: 25.98 +0.23 +0.87% 17:38 02/13 EST
OPEN
25.50
PREV CLOSE
25.64
HIGH
26.16
LOW
25.50
VOLUME
1.16M
TURNOVER
--
52 WEEK HIGH
27.92
52 WEEK LOW
12.72
MARKET CAP
5.24B
P/E (TTM)
-9.5982
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at IMVT last week (0209-0213)?
Weekly Report · 14h ago
Stifel Nicolaus Keeps Their Buy Rating on Immunovant (IMVT)
TipRanks · 5d ago
Immunovant (IMVT) Gets a Buy from Oppenheimer
TipRanks · 6d ago
Undervalued Potential in Difficult-to-Treat RA: Buy Rating on Immunovant Driven by IMVT-1402’s Differentiated Profile and Underappreciated Market Opportunity
TipRanks · 6d ago
Immunovant Rides Brepocitinib Momentum Into 2026
TipRanks · 6d ago
Immunovant Is Maintained at Buy by Guggenheim
Dow Jones · 02/09 14:55
Guggenheim Maintains Buy on Immunovant, Raises Price Target to $44
Benzinga · 02/09 14:44
Immunovant price target raised to $23 from $22 at Truist
TipRanks · 02/09 12:25
More
About IMVT
Immunovant, Inc. is a clinical-stage immunology company enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-fragment crystallizable receptor (FcRn) technology, the Company is developing targeted therapies to meet the complex and variable needs of people with autoimmune diseases. Its product pipeline includes its product candidates, IMVT-1402 and batoclimab, both of which are novel, fully human, monoclonal antibodies that target the neonatal FcRn. Subcutaneous injections, IMVT-1402 and batoclimab have been observed to reduce immunoglobulin G (IgG) antibody levels, which has provided evidence supporting the use of an anti-FcRn antibody in disease areas associated with high levels of pathogenic IgG antibodies. The Company is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD).

Webull offers Immunovant Inc stock information, including NASDAQ: IMVT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMVT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMVT stock methods without spending real money on the virtual paper trading platform.